Atara Biotherapeutics (ATRA) Enterprise Value (2013 - 2026)

Atara Biotherapeutics has reported Enterprise Value for 14 years, with the latest figure at -$8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 39.31% year-over-year to -$8.4 million; the trailing twelve-month figure through Mar 2026 stood at -$8.4 million (up 39.31% YoY), and the FY2025 full-year result was -$8.5 million, up 66.24% from the prior year.
• Enterprise Value for Q1 2026 stood at -$8.4 million, up from -$8.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$8.4 million in Q1 2026, with the low at -$265.4 million in Q3 2022.
• Historically, Enterprise Value has averaged -$65.8 million across 5 years, with a median of -$46.0 million in 2023.
• The largest YoY upside for Enterprise Value was 80.71% in 2022 against a maximum downside of 134.04% in 2022.
• Atara Biotherapeutics' Enterprise Value stood at -$242.8 million in 2022, then soared by 78.7% to -$51.7 million in 2023, then soared by 51.33% to -$25.2 million in 2024, then jumped by 66.24% to -$8.5 million in 2025, then climbed by 1.18% to -$8.4 million in 2026.
• The last three Enterprise Value figures came in at -$8.4 million (Q1 2026), -$8.5 million (Q4 2025), and -$13.7 million (Q3 2025), per Business Quant data.